Vancouver, British Columbia, Canada, June 20, 2025 – PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA) is pleased to announce that it has engaged the services of Fairfax Partners Inc. (“Fairfax”) of Vancouver, BC to provide investor relations, communications infrastructure and marketing services. The services agreement with Fairfax will remain in effect for a period of six (6) months commencing on June 20, 2025. In accordance with the terms and conditions of the services agreement and as consideration for the services provided by Fairfax, the Company has agreed to pay a monthly cash fee of $5,000, plus applicable taxes. Fairfax Partners Inc. is an unrelated third party service provider. Fairfax Partners Inc., including its owners and directors, does not hold, directly or indirectly, any ownership or interest in the securities of the Company.
Acceleration of Warrant Expiration Date The Company also provides an update regarding the acceleration of the expiration date of 4,300,464 share purchase warrants issued by the Company on or about May 27, 2024, which
warrants are exercisable for $0.17 per share, as previously announced on January 29, 2025 (the “Warrants”). As the closing price of the Company’s shares, as quoted by the Canadian Securities Exchange, was equal to or greater than $0.23 per share for a 10 consecutive trading day period ending on June 9, 2025, the expiration date of the Warrants has automatically been accelerated to July 9, 2025.
About PanGenomic Health
PanGenomic Health is a precision health company that has developed a self-care digital platform
to deliver personalized, evidence-based information about natural treatments. The Company’s
initial focus is to support mental health. Registered as a British Columbia benefit company,
PanGenomic Health’s mission is to promote and improve the health and wellness of people and
society by providing a technology platform that identifies plant-based solutions tailored to the
health profile of each individual.
For more information, please contact:
Jerry Lai, Investor Relations
PanGenomic Health Inc.
+1 778 743 4642
ir@pangenomic.com
Fairfax Partners Inc.
Daniel Southan-Dwyer, President
+1 604 366 6277
connect@fairfaxpartners.ca
This news release includes certain statements that may be deemed “forward-looking statements”,
including statements respecting the services to be provided by PanGenomic Health and the
consideration to be paid to PanGenomic Health. The use of any of the words “anticipate”,
“continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar
expressions are intended to identify forward looking statements. Although PanGenomic Health
believes that the expectations and assumptions on which the forward-looking statements are
based are reasonable, undue reliance should not be placed on the forward-looking statements
because PanGenomic Health can give no assurance that they will prove to be correct. Since
forward-looking statements address future events and conditions, by their very nature they involve
inherent risks and uncertainties. These statements speak only as of the date of this News
Release. Actual results could differ materially from those currently anticipated due to a number of
factors and risks including various risk factors discussed in PanGenomic Health’s disclosure
documents which can be found under PanGenomic Health’s profile on www.sedarplus.ca.
The Canadian Securities Exchange has neither approved nor disapproved the information
contained herein and does not accept responsibility for the adequacy or accuracy of this
news release
